This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MEDNAX's (MD) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
MEDNAX's (MD) third-quarter results reflect growing revenues driven by rising patient volumes, partly offset by higher general and administrative expenses.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Molina Healthcare's (MOH) Q3 Earnings Beat Mark, Fall Y/Y
by Zacks Equity Research
Molina Healthcare (MOH) Q3 earnings gain from better revenues, partly offset by steep expenses.
Molina (MOH) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.54% and 4.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Universal Health's (UHS) Q3 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q3 earnings are likely to have suffered elevated costs, partly offset by better patient volumes.
Centene (CNC) Gears Up for Q3 Earnings: What Lies Ahead?
by Zacks Equity Research
Centene's (CNC) third-quarter results are likely to reflect better revenues and membership growth.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
What's in Store for Teladoc Health's (TDOC) Earnings in Q3?
by Zacks Equity Research
Teladoc Health (TDOC) is likely to report a strong revenue outperformance for the third quarter, driven by broad-based momentum across its business and a sharp acceleration in visit-volume growth.
Molina (MOH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Molina (MOH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should SPDR S&P MidCap 400 ETF (MDY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MDY
UnitedHealth (UNH) Beats on Q3 Earnings & Revenues, Ups View
by Zacks Equity Research
UnitedHealth (UNH) Q3 results reflect revenue growth at both the business units and increased membership.
Encompass Health (EHC) Rides on Solid Revenues, Expansion Plans
by Zacks Equity Research
Encompass Health (EHC) continues to gain, courtesy of sustained growth in revenues, sound expansion endeavors across the United States and a robust 2021 business outlook.
Anthem's (ANTM) MA Members to be Covered Under Highly Rated Plans
by Zacks Equity Research
Anthem's (ANTM) 72% Medicare Advantage members to be covered under highly rated plans starting 2022. The ratings reflect the company's commitment to provide better healthcare.
Molina (MOH) to Buy AgeWell's Medicaid Long Term Care Business
by Zacks Equity Research
Molina (MOH) inks a deal to acquire certain assets of AgeWell New York's Medicaid Managed Care Business for a value of $110M.
Should SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPMD
Why Should You Hold Onto Anthem (ANTM) in Your Portfolio?
by Zacks Equity Research
A solid positioning in an ever-growing industry along with strong fundamentals make Anthem (ANTM) a good fit for investment gains.
Centene (CNC) Expands Medicare Advantage Offerings in 36 States
by Zacks Equity Research
Centene (CNC) boosts its Medicare Advantage offerings in 1,575 counties across 36 states in a bid to provide affordable and quality healthcare.
Why Should You Hold Molina Healthcare (MOH) in Your Portfolio?
by Zacks Equity Research
Riding high on strategic measures and membership growth, Molina Healthcare (MOH) holds enough potential to reap benefits for investors.
Humana (HUM), Kelsey-Seybold Clinic Tie Up for Better Healthcare
by Zacks Equity Research
Humana (HUM) inks a deal with Kelsey-Seybold Clinic in Houston to offer its Humana Medicare Advantage HMO members enriched healthcare facilities.
3 HMO Stocks That Outperformed the S&P Index in a Year's Time
by Srijita Guha
Membership growth, mergers and buyouts, and investment in technology are likely to aid health insurance companies like ANTM, MOH, and UNH to outperform the S&P Index.
Why Should You Hold Centene (CNC) in Your Portfolio Now?
by Zacks Equity Research
Riding high on strategic initiatives and operational excellence, Centene (CNC) holds potential to reap benefits for investors.
Humana (HUM), Curant Health Team Up to Aid Chronic Patients
by Zacks Equity Research
Humana (HUM) inks a deal with Curant Health to offer its members with chronic diseases enriched healthcare facilities.
Here's Why You Should Hold Molina Healthcare (MOH) Stock Now
by Zacks Equity Research
Riding high on its rising membership, a healthy revenue stream and restructuring measures, Molina Healthcare (MOH) holds potential to reap benefits for investors.
Centene vs. Anthem: Which is a Better-Positioned Stock?
by Zacks Equity Research
Centene (CNC) and Anthem (ANTM) are poised to grow in the thriving health insurance industry. On comparative evaluation, we try to discover which stock is more profitable, based on the fundamentals.
Why Should You Hold onto Anthem (ANTM) in Your Portfolio?
by Zacks Equity Research
Riding high on growing revenues, solid guidance and strategic initiatives, Anthem (ANTM) holds potential to reap benefits for investors.